SEC Info - Atara Biotherapeutics, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Atara Biotherapeutics, Inc.
CA
SEC # 1604464

Related Registrant:

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

1/9/24	424B5	1	About This Prospectus	3
4/26/24	DEF 14A	1	Appendix A	2
		1	Appendix B	2
		1	Appendix C	2
		1	Appendix D	2
		1	Appendix E	2
3/28/24	10-K	1	Business	1
		1	Certain Relationships and Related Transactions, and Director Independence	1
		1	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	1
5/9/24	10-Q	1	Condensed Consolidated Balance Sheets	4
		1	Condensed Consolidated Statements of Cash Flows	4
8/8/23	10-Q	1	Condensed Consolidated Statements of Changes in Stockholders' Equity	2
5/9/24	10-Q	1	Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)	2
		1	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	3
5/8/23	10-Q	1	Condensed Consolidated Statements of Operations and Comprehensive Loss	1
3/28/24	10-K	1	Consolidated Balance Sheets	1
		1	Consolidated Statements of Cash Flows	1
		1	Consolidated Statements of Operations and Comprehensive Loss	1
		1	Consolidated Statements of Stockholders' Equity (Deficit)	1
5/9/24	10-Q	1	Controls and Procedures	5
3/28/24	10-K	1	Cybersecurity	1
1/9/24	424B5	1	Description of Capital Stock	3
		1	Description of Debt Securities	2
		1	Description of Pre-Funded Warrants	1
		1	Description of Rights	2
		1	Description of Units	2
		1	Description of Warrants	2
		1	Dilution	3
3/28/24	10-K	1	Directors, Executive Officers and Corporate Governance	1
		1	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	1
4/26/24	DEF 14A	1	Executive Compensation	3
		1	Executive Officers	2
5/9/24	10-Q	1	Exhibits	4
3/28/24	10-K	1	Exhibits, Financial Statement Schedules	1
1/9/24	424B5	1	Experts	3
3/28/24	10-K	1	Financial Statements and Supplementary Data	1
		1	Form 10-K Summary	1
4/26/24	DEF 14A	1	Householding of Proxy Materials	2
1/9/24	424B5	1	Incorporation of Certain Information by Reference	3
4/26/24	DEF 14A	1	Information Regarding the Board of Directors and Corporate Governance	2
1/9/24	424B5	1	Legal Matters	3
		1	Legal Ownership of Securities	2
5/9/24	10-Q	1	Legal Proceedings	5
		1	Management's Discussion and Analysis of Financial Condition and Results of Operations	5
3/28/24	10-K	1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
1/9/24	424B5	1	Material U.S. Federal Income Tax Consequences to Investors	1
3/28/24	10-K	1	Mine Safety Disclosures	1
4/26/24	DEF 14A	1	Nominees for Election for a Three-Year Term Expiring at the 2027 Annual Meeting	2
5/9/24	10-Q	1	Notes to Condensed Consolidated Financial Statements	4
3/28/24	10-K	1	Notes to Consolidated Financial Statements	1
1/9/24	424B5	1	Offering, The	3
5/9/24	10-Q	1	Other Information	5
4/26/24	DEF 14A	1	Other Matters	2
3/28/24	10-K	1	Part I	1
		1	Part Ii	1
		1	Part Iii	1
		1	Part Iv	1
1/9/24	424B5	1	Plan of Distribution	3
3/28/24	10-K	1	Power of Attorney (included on signature page)	1
1/3/24	S-8	1	Power of Attorney (included on the signature page of this Form S-8)	1
11/1/23	S-3	1	Power of Attorney (see signature page hereto)	1
3/28/24	10-K	1	Principal Accounting Fees and Services	1
		1	Properties	1
4/26/24	DEF 14A	1	Proposal 1: Election of Directors	2
		1	Proposal 2: Advisory Vote on Executive Compensation	2
		1	Proposal 3: Ratification of the Selection of Independent Registered Public Accounting Firm	2
		1	Proposal 4: Approval of the Company's 2024 Equity Incentive Plan	2
		1	Proposal 5: Approval of Automatic Annual Increase to Company's 2024 Equity Incentive Plan	2
		1	Proposal 6: Approval of Increase in Number of Common Stock Available for Issuance Under Company's 2014 Employee Stock Purchase Plan	2
		1	Proposal 7: Amendment of the Company's Certificate of Incorporation to Effect a Reverse Stock Split	2
		1	Proposal 8: Adjournment of Annual Meeting for Further Solicitation	2
1/9/24	424B5	1	Prospectus Summary	3
		1	Prospectus Supplement Summary	1
5/9/24	10-Q	1	Quantitative and Qualitative Disclosures about Market Risk	5
4/26/24	DEF 14A	1	Questions and Answers About These Proxy Materials and Voting	2
3/28/24	10-K	1	Report of Independent Registered Public Accounting Firm	1
		1	Reserved	1
5/9/24	10-Q	1	Risk Factors	8
4/26/24	DEF 14A	1	Security Ownership of Certain Beneficial Owners and Management	2
3/28/24	10-K	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	1
5/9/24	10-Q	1	Signatures	4
11/17/23	424B3	1	Special Note Regarding Forward Looking Statements	1
1/9/24	424B5	1	Special Note Regarding Forward-Looking Statements	2
		1	Table of Contents	3
		1	The Offering	3
4/26/24	DEF 14A	1	Transactions with Related Persons and Indemnification	2
3/28/24	10-K	1	Unresolved Staff Comments	1
1/9/24	424B5	1	Use of Proceeds	3
		1	Where You Can Find More Information	3

↑Top

Atara Biotherapeutics, Inc. CA SEC # 1604464

190 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Atara Biotherapeutics, Inc.
CA
SEC # 1604464

190 Topics
within the